dbACP: A Comprehensive Database of Anti-Cancer Peptides

dbacp05486

General Description

Peptide name : Pexiganan

Source/Organism : Analog of African clawed frog

Linear/Cyclic : Linear

Chirality : L

Sequence Information

Sequence : GIGKFLKKAKKFGKAFVKILKK

Peptide length: 22

C-terminal modification: Linear

N-terminal modification : Amidation

Non-natural peptide information: None

Activity Information

Assay type : MTT/MTS assay

Assay time : 72h

Activity : LC50 : 13 at 100 µM

Cell line : OVRCAR-3

Cancer type : Ovarian cancer

Other activity : Anti-microbial activity

Physicochemical Properties

Amino acid composition bar chart :

Molecular mass : 2478.1585 Dalton

Aliphatic index : 0.931

Instability index : -6.1636

Hydrophobicity (GRAVY) : -0.159

Isoelectric point : 10.903

Charge (pH 7) : 8.7511

Aromaticity : 0.136

Molar extinction coefficient (cysteine, cystine): (0, 0)

Hydrophobic/hydrophilic ratio : 1.44444444

hydrophobic moment : 0.4174

Missing amino acid : C,R,W,H,Q,T,P,M,E,S,D,Y,N

Most occurring amino acid : K

Most occurring amino acid frequency : 9

Least occurring amino acid : V

Least occurring amino acid frequency : 1

Structural Information

3D structure :

Secondary structure fraction (Helix, Turn, Sheet): (0.5, 0.1, 0.3)

SMILES Notation: CC[C@H](C)[C@H](NC(=O)CN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O)[C@@H](C)CC)C(C)C

Secondary Structure :

Method Prediction
GOR HHHHHHHHHHHHHHHHHHHHHH
Chou-Fasman (CF) EEHHHHHHHHHHHHHEECCCCC
Neural Network (NN) CCHHHHHHHHHHHHHHHHHHHC
Joint/Consensus CCHHHHHHHHHHHHHHHHHHHC

Molecular Descriptors and ADMET Properties

Molecular Descriptors: Click here to download

ADMET Properties: Click here to download

Cross Referencing databases

Pubmed Id : 24587350

Uniprot : Not available

PDB : Not available

CancerPPD : Click here

ApIAPDB : Not available

CancerPPD2 ID : Not available

Reference

1 : Huang W, et al. Learning from host-defense peptides: cationic, amphipathic peptoids with potent anticancer activity. PLoS One. 2014; 9:e90397. doi: 10.1371/journal.pone.0090397

Literature

Paper title : Learning from host-defense peptides: cationic, amphipathic peptoids with potent anticancer activity.

Doi : https://doi.org/10.1371/journal.pone.0090397

Abstract : Cationic, amphipathic host defense peptides represent a promising group of agents to be developed for anticancer applications. Poly-N-substituted glycines, or peptoids, are a class of biostable, peptidomimetic scaffold that can display a great diversity of side chains in highly tunable sequences via facile solid-phase synthesis. Herein, we present a library of anti-proliferative peptoids that mimics the cationic, amphipathic structural feature of the host defense peptides and explore the relationships between the structure, anticancer activity and selectivity of these peptoids. Several peptoids are found to be potent against a broad range of cancer cell lines at low-micromolar concentrations including cancer cells with multidrug resistance (MDR), causing cytotoxicity in a concentration-dependent manner. They can penetrate into cells, but their cytotoxicity primarily involves plasma membrane perturbations. Furthermore, peptoid 1, the most potent peptoid synthesized, significantly inhibited tumor growth in a human breast cancer xenotransplantation model without any noticeable acute adverse effects in mice. Taken together, our work provided important structural information for designing host defense peptides or their mimics for anticancer applications. Several cationic, amphipathic peptoids are very attractive for further development due to their high solubility, stability against protease degradation, their broad, potent cytotoxicity against cancer cells and their ability to overcome multidrug resistance.